Antimicrobial Stewardship

Utilizing a newer technology, investigators wanted to see if a reduction in time led to clinically significant antimicrobial adjustments.

A multicenter study looked at treating these infections with omadacycline.

Study links inappropriate, off-guideline antibiotics to increased, avoidable allergic and adverse events in children.

A medical center wanted to review prescribing and documentation practices for their pharmacists.

With limitations on fidaxomicin at their facility, a hospital looked at vancomycin usage to determine if they needed to align with the new IDSA/SHEA CDI treatment guideline.

A health system piloted a program that explored having an infectious disease pharmacist aid in guiding treatment.

Designing a transitions of care stewardship program and engaging all stakeholders can help cut down on unnecessary antibiotic prescriptions.

Can clinicians rely on dosing strategy to avoid acute kidney injury for patients receiving vancomycin with a β-lactam like piperacillin-tazobactam?

Jason Pogue, PharmD, BCPS, BCIDP, shares key takeaways from his 2 presentations at MAD-ID 2022, including a new alternative to the SPACE acronym, as well as how to navigate any anxieties around oral carbapenems.

A MAD-ID 2022 poster sought to better understand the current antibiotic prescribing patterns at adult primary care clinics affiliated with Maimonides Medical Center in New York.

A study looked at the utilization of the technology with this antibiotic class in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).

At MAD-ID 2022, Payal K. Patel, MD, MPH, FIDSA, discussed how COVID-19 misinformation and lags in diagnostics contributed to inappropriate antibiotic use and offers some way to combat this trend.

“Clearly, stewardship is a team operation. It starts [with] the leadership, the clinical pharmacy, and coordination with infectious disease physicians truly has to be synergistic,” Goetz said in the keynote address at MAD-ID 2022.

Among community-acquired pneumonia (CAP) outpatients, 49% were prescribed unnecessary antibiotics.

Leveraging antimicrobial stewardship programs was crucial to ensure COVID-19 hospital inpatients received monoclonal antibody therapy quickly and safely.

To reduce the risk of antimicrobial resistance, rapid laboratory diagnostics are needed to identify the pathogens in hospital patients with COVID-19 and sepsis.

Over half of patients admitted with positive SARS-CoV-2 testing received antibiotics, but evidence of bacterial infection is uncovered in far fewer cases. We may already be seeing the effects of antibiotic overprescribing.

Tetracycline-class antibiotic, omadacycline (Nuzyra), is FDA approved for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), and is also being studied for other potential indications.

The organization has its upcoming antimicrobial stewardship meeting in less than two weeks, and offers professional education and training in infectious diseases with a special emphasis on antimicrobial stewardship.

Antibiotic-resistant strains of the dangerous superbug C difficile have been identified in pigs and humans, suggesting zoonotic transmission is possible.

In the latest column from SIDP, clinicians discuss that along with the once-daily dosing for many indications, there are also compelling indications for twice-daily dosing.

Improving stool sample collecting and testing reduced C difficile underdiagnosis.

Researchers sought to assess antibiotic prescriptions associated with COVID-19 outpatient visits in Medicare beneficiary patients over the course of a year during the pandemic.

Investigators performed a systematic review to assess just how strong the association between race and urinary tract infections (UTIs) in children.

Antibiotic overuse is a longstanding problem in the medical community. A new study highlights the benefits of accurate point-of-care testing to differentiate between bacteria and viruses.

Entasis Therapeutics gave 2 oral presentations at ECCMID today detailing results of their ATTACK trial, investigating the safety and efficacy of sulbactam-durlobactam (SUL-DUR) for multidrug-resistant pathogens.

During the pandemic, antibiotic-resistant bacterial infections increased in hospitalized patients who tested positive or negative for COVID-19.

The tactic is seen as a way to ensure supplies of novel drugs in face of resistance crisis.

Investigators used procalcitonin (PCT) levels to guide antibiotic recommendations in pediatric intensive care units. PCT-guided antibiotic stewardship decreased the number of antibiotic days without leading to therapy failure.